Ibio, Inc. · NASDAQ:IBIO

Ibio — Investor Presentation (May 2022)

29 slides from Ibio's investor presentation, May 16, 2022

  1. Slide 1: Growing Tomorrow’s Biologics Corporate Presentation

    Growing Tomorrow’s Biologics CORPORATE PRESENTATION May 2022 Tom Isett, Chairman & CEO © 2022 iBio, Inc. All Rights Reserved. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continu

  3. Slide 3: iBio Overview

    iBio Overview Drug Discovery Platform Novel screening capabilities with AI-driven design FastPharming® Mfg Platform Proprietary plant-based protein expression system Development & Manufacturing Services Delivering speed, scalability, and sustainability Proprietary Pipeline Addressing cancer, fibrosi

  4. Slide 4: Unique Solution for Some of the Industry’s Biggest Problems

    4 Unique Solution for Some of the Industry’s Biggest Problems 1iiBio estimates; 2Belkhir, L., et. al. (2018) “Carbon footprint of the global pharmaceutical industry and relative impact of its major players”. J Cleaner Production 214:185-194 Biopharmaceutical Development Challenges GlycaneeringSM SOL

  5. Slide 5: Green Protein Expression System

    5 Green Protein Expression System 1 130,000 sf Facility Bacterial Infiltration (Transient Transfection) Protein Production Harvesting Purification & Vialing Seeding & Growth Gene Cloning Mobilization 2 3 4 5 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

  6. Slide 6: The Speed & Scalability of FastPharming

    6 The Speed & Scalability of FastPharming Potentially Enables a Faster, More Efficient Path to the Clinic Time to Drug Substance may vary and does not include product-specific process and assay development work. Mammalian cell culture timelines shown are for illustrative purposes only based upon com

  7. Slide 7: iBio Platform Potentially Enables More Promising Candidates to Reach the Clinic, Faster

    CDMO SERVICES Success Rate <5 in 5,000 7 iBio Platform Potentially Enables More Promising Candidates to Reach the Clinic, Faster 1Paul, et al. NatureReviews Drug Discovery. (2010) 9, 203–214 Increased Potency with Glycaneering Industry Benchmarks to Reach IND1 Time >4 Years Cost >$20M Glycaneering T

  8. Slide 8: Reducing Single-Use Plastic Disposables in Upstream Processing

    8 117th Annual Report and Summary of Biopharmaceutical Manufacturing Capacity and Production https://www.biopharma.com/TRENDS.pdf Reducing Single-Use Plastic Disposables in Upstream Processing VS >85% of pre-commercial bioprocesses involve single-use plastic disposables1 Seeds Stone Wool Purified Wa

  9. Slide 9: Pipeline Advancing Vertically – and Horizontally

    9 Pipeline Advancing Vertically – and Horizontally ​ ​ ​ ​ ​

  10. Slide 10: Therapeutics: Oncology & Fibrosis

    Therapeutics Oncology & Fibrosis ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

  11. Slide 11: Deploying AI-based Target ID & Glycaneering in Immuno-Oncology

    THERAPEUTICS 11 Deploying AI-based Target ID & Glycaneering in Immuno-Oncology to Create More, Higher-Quality, Shots-on-Goal Access to RubrYc AI Discovery Platform Glycaneering Technology iBio Discovery & More shots-on-goal, Dev Approach 1 sooner Identifying failures 2 earlier, saving costs Accelera

  12. Slide 12: IBIO-101 Stimulates Anti-tumor Immunity via anti-CD25 Treg Depletion

    THERAPEUTICS IBIO-101 Stimulates Anti-tumor Immunity via anti-CD25 Treg Depletion 12 1Data on file Treg = Regulatory T Cells; Teff = Effector T Cells; ADCC = Antibody Dependent Cellular Cytotoxicity 2nd gen IL-2 sparing anti-CD25 antibody electively targets Tregs without blocking IL-2 signaling to T

  13. Slide 13: IBIO-101/RTX-003 Inhibits Tumor Growth, Alone and in Combination

    THERAPEUTICS 13 IBIO-101/RTX-003 Inhibits Tumor Growth, Alone and in Combination 1In vivo xenograft mouse model of lymphoma; Administration: 3x / week, i.p.; n=5 per group 2In vivo transgenic hCD25 mouse model; Admin: i.p. 3X / week at a single dose (1.5 mg/Kg) in combination with 2.5 mg/Kg of anti-

  14. Slide 14: IBIO-101 Has Showed Equivalent Efficacy and Potency with RTX-003

    THERAPEUTICS 14 IBIO-101 Has Showed Equivalent Efficacy and Potency with RTX-003 Enabled engineering of more potent version without incremental IP access costs Phan, et al. "Plant-Based Expression and Glyco-Engineering of Novel IL-2 Signaling Permissive Anti-CD25 Antibodies for Effective Treg Deplet

  15. Slide 15: Endostatin Derived Drugs for Fibrotic Disorders and Fibrotic Tumors

    THERAPEUTICS 15 Endostatin Derived Drugs for Fibrotic Disorders and Fibrotic Tumors Endostatin E4 for Fibrotic Tumors Reduces fibrosis by impacting extracellular matrices1 Pre-clinical data shows reduced fibrosis in scleroderma/IPF models & human lung explants1 IBIO-100 Orphan Drug Designation for s

  16. Slide 16: Vaccines: Human Health COVID-19, Animal Health CSFV

    Vaccines Human Health: COVID-19 Animal Health: CSFV ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

  17. Slide 17: Experts Calling for Approaches Like iBio’s DAVi Vaccine Design

    VACCINES 17 Experts Calling for Approaches Like iBio’s “DAVi” Vaccine Design 1 Borio, Bright, and Emanuel, A National Strategy for COVID-19 Medical Countermeasures, JAMA. 2022;327(3):215–216 We need to work towards a 'last dose', not a 'next dose' Antigen-adjuvant combos that may deliver long-lastin

  18. Slide 18: IBIO-202 Nucleocapsid-based Subunit Vaccine

    VACCINES 18 IBIO-202 Nucleocapsid [N]-based Subunit Vaccine May Complement Current and Future Spike [S]-based Vaccines 1 Dai, L. & Gao, G. F. Viral targets for vaccines against COVID-19. Nature Reviews Immunology 21, 73–82 (2021); 2 Fielding CA, et.al., ADNKA overcomes SARS-CoV2-mediated NK cell inh

  19. Slide 19: IBIO-202 Preclinical Data Shows Potential for Protective Immune Responses

    VACCINES IBIO-202 Preclinical Data Shows Potential for Protective Humoral 19 & Cell-mediated Immune Responses Ctrl. IBIO-202 0 1 2 3 4 IFN-g Secreting cells/106 ✱✱✱✱ High number of N-specific IFNg secreting T cells indicates immune activation Ctrl. IBIO-202 0 1 2 3 4 IL-5 Secreting cells/106 ns Ctrl

  20. Slide 20: Emerging Studies Reinforce Value of IBIO-202’s Design

    VACCINES 20 Emerging Studies Reinforce Value of IBIO-202’s Design 1Kundu, R., Narean, J.S., Wang, L. et al. Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. Nat Commun 13, 80 (2022) 2Cohen, et al. Cell Reports Medicine. July 2021 Potential fo

  21. Slide 21: IBIO-202 Appears Differentiated in a Crowded Field

    VACCINES 9 4 2 1 N only (US & global companies) ■ N only (academic, government, ex-US) ■S+N+M or other combination ■S+N 21 IBIO-202 Appears Differentiated in a Crowded Field 1Dangi, Tanushree et al. “Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2.” Cell report

  22. Slide 22: Classical Swine Fever Animal Health

    Classical Swine Fever Animal Health ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

  23. Slide 23: Classical Swine Fever is a Significant World-Wide Economic Burden

    VACCINES 23 Classical Swine Fever [CSF] is a Significant World-Wide Economic Burden and Puts Major Export Markets at Risk • CSF is a priority agricultural biothreat • CSF poses a risk to $7.0B US swine exports • Only 38 countries are currently CSF-free • No vaccines are approved in the US (only a fe

  24. Slide 24: IBIO-400 Offers Potential Benefits Over Current Alternatives

    VACCINES 24 IBIO-400 Offers Potential Benefits Over Current Alternatives 1 In studies IBIO-400: E2 protein subunit vaccine CSF Virus Provides single-dose protection against CSF1 Supports important trade requirements, unlike live virus vaccines Potential to be the first CSF vaccine fully licensed by

  25. Slide 25: In Summary

    In Summary ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

  26. Slide 26: Our Leadership Team Brings Drug Development & Bioprocessing Experience

    Our Leadership Team Brings Drug Development & Bioprocessing Experience 26 Tom Isett CEO & Chairman Martin Brenner, DVM, Ph.D. CSO Robert Lutz, MBA CFBO Lisa Middlebrook CHRO Marc Banjak GC ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

  27. Slide 27: Strong and Growing IP Estate Provides Exclusivity for iBio’s Pipeline

    27 Strong and Growing IP Estate Provides Exclusivity for iBio’s Pipeline Issued Patents (30 U.S.) 104 Active Applications (10 U.S.) 29 More Applications progressing to filing Patent Protection Includes: • IP for iBio’s pipeline products and vaccines • IP related to the FastPharming Protein Expressio

  28. Slide 28: Financial Overview

    28 Financial Overview § Publicly traded (NYSEA: IBIO) since Jan 2008 § Approximately $48.6M in cash and cash equivalents plus investments in debt securities, excluding $5.9M of restricted cash (31 Mar 2022) § Approximately 218.2M common shares & 17.1M options, restricted stock units and warrants out

  29. Slide 29: iBio: Leveraging Capabilities to Create Shareholder Value

    29 iBio: Leveraging Capabilities to Create Shareholder Value Providing better options for the $6B Bioprocess industry Leveraging platform for both in-licensing and out-licensing with captured supply agreements Selectively out-licensing assets and securing FastPharming supply contracts Advancing our

iBio — Investor Presentation (May 2022) on 6ix